Mast cells and pulmonary fibrosis. Identification of a histamine releasing factor in bronchoalveolar lavage fluid.
As elevated bronchoalveolar lavage (BAL) fluid histamine levels are noted in patients with pulmonary fibrosis (PF), we assayed BAL fluid from 16 patients with PF for the presence of a histamine releasing factor (HRF). HRF activity was assayed by measuring release of the preformed mast cell-derived mediators, histamine, or beta-hexosaminidase (beta-hex) from a purified population of IL-3 dependent mouse bone marrow derived mast cells (MBMMC) or human blood basophils. Mean BAL cell free histamine levels in the patients with PF was 1226 +/- 1349 pg/ml, whereas BAL histamine levels in a comparison group of six non-PF patients was 118 +/- 60 pg/ml. HRF was significantly elevated in BAL fluid of patients with PF (mean beta-hex release 24.5 +/- 12.9%; range 6.8 to 52.4%) compared to the non-PF group of patients (mean beta-hex release 7.9 +/- 7.7%; range 1.8 to 20.7%). The PF HRF not only degranulated MBMMC, but also induced the generation of the arachidonic acid metabolite leukotriene C4 from MBMMC (24.6 +/- 4.2 ng leukotriene C4/10(6) MBMMC). The PF HRF did not appear to be a cytokine previously identified in BAL fluid of patients with PF (i.e., platelet derived growth factor or insulin growth factor-1) or a human cytokine able to degranulate human basophils (i.e., IL-1, or granulocyte-macrophage-CSF) as these recombinant human cytokines did not induce MBMMC beta-hex release. Physicochemical characterization of the HRF revealed that it was relatively heat stable, pronase sensitive and on Sephadex G-75 and G-200 column chromatography had an apparent molecular mass of 30 to 50 kDa. The ability of PF BAL to induce beta-hex release from MBMMC was not dependent on IgE as unsensitized or lactic acid treated MBMMC release similar amounts of beta-hex compared to MBMMC sensitized with IgE. Thus, BAL fluid of patients with PF contains an HRF that induces beta-hex release from MBMMC via an IgE-independent mechanism. The presence of the HRF could explain elevated BAL histamine levels in patients with PF.
Broide
D H
DH
Department of Medicine, University of California, San Diego 92103.
Smith
C M
CM
Wasserman
S I
SI
D001992:Bronchoalveolar Lavage Fluid / Q000032:analysis*; D003115:Colony-Stimulating Factors / Q000502:physiology; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000502:physiology; D006632:Histamine / Q000032:analysis; D006636:Histamine Release; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000502:physiology; D008297:Male; D008407:Mast Cells / Q000502:physiology*; D008875:Middle Aged; D011506:Proteins / Q000032:analysis* / Q000494:pharmacology; D011658:Pulmonary Fibrosis / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology; D001619:beta-N-Acetylhexosaminidases / Q000378:metabolism
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D007375:Interleukin-1; D011506:Proteins; D014409:Tumor Necrosis Factor-alpha; D006632:Histamine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D001619:beta-N-Acetylhexosaminidases